292 related articles for article (PubMed ID: 35571495)
1. Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease.
Dwomoh L; Tejeda GS; Tobin AB
Neuronal Signal; 2022 Apr; 6(1):NS20210004. PubMed ID: 35571495
[TBL] [Abstract][Full Text] [Related]
2. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa M; Hesse S; Bradley SJ
Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
[TBL] [Abstract][Full Text] [Related]
3. M1 muscarinic acetylcholine receptor in Alzheimer's disease.
Jiang S; Li Y; Zhang C; Zhao Y; Bu G; Xu H; Zhang YW
Neurosci Bull; 2014 Apr; 30(2):295-307. PubMed ID: 24590577
[TBL] [Abstract][Full Text] [Related]
4. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.
Davie BJ; Christopoulos A; Scammells PJ
ACS Chem Neurosci; 2013 Jul; 4(7):1026-48. PubMed ID: 23659787
[TBL] [Abstract][Full Text] [Related]
5. Bitopic Binding Mode of an M
Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
[TBL] [Abstract][Full Text] [Related]
6. Structural Features of Iperoxo-BQCA Muscarinic Acetylcholine Receptor Hybrid Ligands Determining Subtype Selectivity and Efficacy.
Wakeham MCL; Davie BJ; Chalmers DK; Christopoulos A; Capuano B; Valant C; Scammells PJ
ACS Chem Neurosci; 2022 Jan; 13(1):97-111. PubMed ID: 34905693
[TBL] [Abstract][Full Text] [Related]
7. A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice.
Abd-Elrahman KS; Sarasija S; Colson TL; Ferguson SSG
Br J Pharmacol; 2022 Apr; 179(8):1769-1783. PubMed ID: 34820835
[TBL] [Abstract][Full Text] [Related]
8. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.
Bradley SJ; Bourgognon JM; Sanger HE; Verity N; Mogg AJ; White DJ; Butcher AJ; Moreno JA; Molloy C; Macedo-Hatch T; Edwards JM; Wess J; Pawlak R; Read DJ; Sexton PM; Broad LM; Steinert JR; Mallucci GR; Christopoulos A; Felder CC; Tobin AB
J Clin Invest; 2017 Feb; 127(2):487-499. PubMed ID: 27991860
[TBL] [Abstract][Full Text] [Related]
9. M1 muscarinic acetylcholine receptor dysfunction in moderate Alzheimer's disease pathology.
Yi JH; Whitcomb DJ; Park SJ; Martinez-Perez C; Barbati SA; Mitchell SJ; Cho K
Brain Commun; 2020; 2(2):fcaa058. PubMed ID: 32766549
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between the M
Thompson KJ; Tobin AB
Cell Signal; 2020 Jun; 70():109545. PubMed ID: 31978506
[TBL] [Abstract][Full Text] [Related]
11. Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias.
van der Westhuizen ET; Choy KHC; Valant C; McKenzie-Nickson S; Bradley SJ; Tobin AB; Sexton PM; Christopoulos A
Front Pharmacol; 2020; 11():606656. PubMed ID: 33584282
[TBL] [Abstract][Full Text] [Related]
12. 6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M
Jörg M; van der Westhuizen ET; Khajehali E; Burger WAC; White JM; Choy KHC; Tobin AB; Sexton PM; Valant C; Capuano B; Christopoulos A; Scammells PJ
ACS Chem Neurosci; 2019 Mar; 10(3):1099-1114. PubMed ID: 30547573
[TBL] [Abstract][Full Text] [Related]
13. Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study.
Shiozaki K; Iseki E; Hino H; Kosaka K
J Neurol Sci; 2001 Dec; 193(1):23-8. PubMed ID: 11718746
[TBL] [Abstract][Full Text] [Related]
14. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
Verma S; Kumar A; Tripathi T; Kumar A
J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
[TBL] [Abstract][Full Text] [Related]
15. Surface modified nano-lipid drug conjugates of positive allosteric modulators of M1 muscarinic acetylcholine receptor for the treatment of Alzheimer's disease.
Chintamaneni PK; Krishnamurthy PT; Rao PV; Pindiprolu SS
Med Hypotheses; 2017 Apr; 101():17-22. PubMed ID: 28351483
[TBL] [Abstract][Full Text] [Related]
16. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia.
Foster DJ; Choi DL; Conn PJ; Rook JM
Neuropsychiatr Dis Treat; 2014; 10():183-91. PubMed ID: 24511233
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284.
Smith DL; Davoren JE; Edgerton JR; Lazzaro JT; Lee CW; Neal S; Zhang L; Grimwood S
Mol Pharmacol; 2016 Sep; 90(3):177-87. PubMed ID: 27382013
[TBL] [Abstract][Full Text] [Related]
19. Novel M(1) allosteric ligands: a patent review.
Kuduk SD; Beshore DC
Expert Opin Ther Pat; 2012 Dec; 22(12):1385-98. PubMed ID: 23092292
[TBL] [Abstract][Full Text] [Related]
20. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
Conn PJ; Jones CK; Lindsley CW
Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
